{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:58:40Z","timestamp":1777636720642,"version":"3.51.4"},"reference-count":42,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2022.2090152","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T10:22:47Z","timestamp":1655461367000},"page":"888-893","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["QALYs and ambulatory status: societal preferences for healthcare decision making"],"prefix":"10.1080","volume":"25","author":[{"given":"Lorna L.","family":"Freath","sequence":"first","affiliation":[{"name":"Animal and Plant Health, Animal and Plant Health Agency, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-4689","authenticated-orcid":false,"given":"Alistair S.","family":"Curry","sequence":"additional","affiliation":[{"name":"Genesis Research, West One, Genesis Research LLC, Newcastle upon Tyne, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M. W.","family":"Cork","sequence":"additional","affiliation":[{"name":"Genesis Research, West One, Genesis Research LLC, Newcastle upon Tyne, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana F.","family":"Audhya","sequence":"additional","affiliation":[{"name":"Global Market Access, Sarepta Therapeutics Inc, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine L.","family":"Gooch","sequence":"additional","affiliation":[{"name":"Global Market Access, Sarepta Therapeutics Inc, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_3_4_3_1","unstructured":"National Council on Disability. Quality-adjusted life years and the devaluation of life with disability; 2019."},{"key":"e_1_3_4_4_1","unstructured":"Institute for Clinical and Economic Review. Cost-effectiveness the QALY and the evLYG. 2021; [cited 2021 Jun 11]; Available from: https:\/\/icer.org\/our-approach\/methods-process\/cost-effectiveness-the-qaly-and-the-evlyg\/."},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/jme.21.3.144"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-74"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.2627"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1744133118000154"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462399154138"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/jme.13.3.117"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/jme.17.4.181"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jme.17.4.185"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199711000-00002"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-020-00270-3"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/09638288.2020.1741701"},{"key":"e_1_3_4_17_1","unstructured":"NICE. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene; Final Scope; 2015."},{"key":"e_1_3_4_18_1","unstructured":"Muscular Dystrophy Campaign. Wheelchair provision for children and adults with muscular dystrophy and other neuromuscular conditions best practice guidelines. 2011."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S214084"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02355-x"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/16549716.2018.1447828"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.2307\/2233468"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-017-0678-9"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200411000-00014"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025119931010"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(09)17723-3"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9801800202"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8510(99)00043-3"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8510(99)00079-2"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X15619389"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00323"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6939-1-1"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1050(199902)8:1<25::AID-HEC398>3.0.CO;2-H"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/1073110519857286"},{"key":"e_1_3_4_35_1","volume-title":"Alternative pricing models for remdesivir and other potential treatments for COVID-19; updated report","author":"Campbell JD","year":"2020","unstructured":"Campbell JD, Whittington MD, Rind DM, et\u00a0al. Alternative pricing models for remdesivir and other potential treatments for COVID-19; updated report. Institute for Clinical and Economic Review; 2020."},{"key":"e_1_3_4_36_1","volume-title":"Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma; final evidence report","author":"Lee SJ","year":"2021","unstructured":"Lee SJ, McQueen RB, Beinfeld M, et\u00a0al. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma; final evidence report. Institute for Clinical and Economic Review; 2021."},{"key":"e_1_3_4_37_1","volume-title":"Voclosporin and belimumab for lupus nephritis: effectiveness and value; evidence report","author":"Tice JA","year":"2021","unstructured":"Tice JA, Mandrik O, Thokala P, et\u00a0al. Voclosporin and belimumab for lupus nephritis: effectiveness and value; evidence report. Institute for Clinical and Economic Review; 2021."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.2092"},{"key":"e_1_3_4_39_1","volume-title":"Multiple criteria decision analysis for health technology assessment","author":"NICE DSU","year":"2011","unstructured":"NICE DSU. Multiple criteria decision analysis for health technology assessment. Sheffield, UK: NICE DSU; 2011."},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.10.001"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.003"},{"key":"e_1_3_4_42_1","unstructured":"Democratic Party. 2020 Democratic party platform. 2020 [2021 Jun 11]. Available from: https:\/\/democrats.org\/where-we-stand\/party-platform\/achievinguniversal-affordable-quality-health-care\/"},{"key":"e_1_3_4_43_1","unstructured":"The Oklahoman. 2020 [cited 2021 Jun 11]. Available from: https:\/\/eu.oklahoman.com\/story\/opinion\/columns\/guest\/2020\/05\/30\/point-of-view-which-states-will-follow-oklahoma-and-ban-discriminatory-health-care-rationing\/60398390007\/"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2022.2090152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:11:52Z","timestamp":1729163512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2022.2090152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2022.2090152"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2022.2090152","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}